CeriBell, Inc. $CBLL Position Lessened by Redmile Group LLC

Redmile Group LLC decreased its position in shares of CeriBell, Inc. (NASDAQ:CBLL) by 11.1% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 386,786 shares of the company’s stock after selling 48,453 shares during the period. CeriBell accounts for approximately 0.5% of Redmile Group LLC’s portfolio, making the stock its 25th biggest position. Redmile Group LLC owned about 1.02% of CeriBell worth $7,090,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently bought and sold shares of CBLL. Royce & Associates LP bought a new stake in shares of CeriBell in the 4th quarter valued at approximately $11,695,000. JPMorgan Chase & Co. raised its position in CeriBell by 8.2% during the third quarter. JPMorgan Chase & Co. now owns 411,180 shares of the company’s stock valued at $4,724,000 after acquiring an additional 31,177 shares in the last quarter. KCM Capital Inc lifted its stake in CeriBell by 40.0% in the first quarter. KCM Capital Inc now owns 1,400,000 shares of the company’s stock valued at $25,662,000 after acquiring an additional 400,000 shares during the last quarter. State of Wyoming acquired a new stake in CeriBell in the first quarter valued at approximately $62,000. Finally, Principal Financial Group Inc. grew its position in CeriBell by 71.9% in the first quarter. Principal Financial Group Inc. now owns 23,180 shares of the company’s stock worth $425,000 after acquiring an additional 9,696 shares in the last quarter.

Insiders Place Their Bets

In related news, major shareholder Tpg Gp A, Llc sold 202,368 shares of CeriBell stock in a transaction on Friday, June 26th. The shares were sold at an average price of $20.12, for a total value of $4,071,644.16. Following the transaction, the insider owned 3,765,054 shares in the company, valued at $75,752,886.48. This trade represents a 5.10% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Joseph Michael Taylor sold 5,500 shares of the business’s stock in a transaction on Thursday, June 11th. The stock was sold at an average price of $18.41, for a total transaction of $101,255.00. Following the transaction, the director directly owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. This represents a 8.20% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold a total of 350,789 shares of company stock worth $6,946,191 in the last ninety days. 20.10% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have recently weighed in on CBLL shares. Weiss Ratings downgraded shares of CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a report on Tuesday, July 14th. Canaccord Genuity Group lowered their target price on shares of CeriBell from $28.00 to $25.00 and set a “buy” rating on the stock in a research report on Tuesday, May 12th. One investment analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, CeriBell has a consensus rating of “Moderate Buy” and a consensus price target of $22.20.

CeriBell Stock Down 1.7%

Shares of CeriBell stock opened at $17.83 on Wednesday. CeriBell, Inc. has a 12-month low of $10.85 and a 12-month high of $24.33. The company has a quick ratio of 10.01, a current ratio of 10.44 and a debt-to-equity ratio of 0.14. The stock has a 50 day moving average price of $18.59 and a two-hundred day moving average price of $19.35. The stock has a market capitalization of $676.47 million, a P/E ratio of -10.94 and a beta of 0.77.

CeriBell (NASDAQ:CBLL) last released its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The firm had revenue of $26.49 million during the quarter, compared to the consensus estimate of $26.09 million. Equities analysts expect that CeriBell, Inc. will post -1.69 earnings per share for the current year.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.